These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7948458)

  • 1. Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disorder.
    Stewart DE; Fairman M; Barbadoro S; Zownir P; Steiner M
    Biol Psychiatry; 1994 Aug; 36(3):201-2. PubMed ID: 7948458
    [No Abstract]   [Full Text] [Related]  

  • 2. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine's spectrum of action in premenstrual syndrome.
    Menkes DB; Taghavi E; Mason PA; Howard RC
    Int Clin Psychopharmacol; 1993; 8(2):95-102. PubMed ID: 8345163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder.
    Nyberg S; Wahlström G; Bäckström T; Sundström Poromaa I
    Psychoneuroendocrinology; 2004 Jul; 29(6):767-77. PubMed ID: 15110926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder.
    Halbreich U; Petty F; Yonkers K; Kramer GL; Rush AJ; Bibi KW
    Am J Psychiatry; 1996 May; 153(5):718-20. PubMed ID: 8615423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
    Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personality traits in LLPDD and normal controls during follicular and luteal menstrual-cycle phases.
    Parry BL; Ehlers CL; Mostofi N; Phillips E
    Psychol Med; 1996 Jan; 26(1):197-202. PubMed ID: 8643759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived poor sleep quality in the absence of polysomnographic sleep disturbance in women with severe premenstrual syndrome.
    Baker FC; Sassoon SA; Kahan T; Palaniappan L; Nicholas CL; Trinder J; Colrain IM
    J Sleep Res; 2012 Oct; 21(5):535-45. PubMed ID: 22417163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a low dose of alcohol on allopregnanolone serum concentrations across the menstrual cycle in women with severe premenstrual syndrome and controls.
    Nyberg S; Andersson A; Zingmark E; Wahlström G; Bäckström T; Sundström-Poromaa I
    Psychoneuroendocrinology; 2005 Oct; 30(9):892-901. PubMed ID: 15979810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls.
    Eriksson E; Sundblad C; Lisjö P; Modigh K; Andersch B
    Psychoneuroendocrinology; 1992; 17(2-3):195-204. PubMed ID: 1438645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine in the treatment of late luteal phase dysphoric disorder.
    Stone AB; Pearlstein TB; Brown WA
    J Clin Psychiatry; 1991 Jul; 52(7):290-3. PubMed ID: 2071558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-endorphin decline in late luteal phase dysphoric disorder.
    Giannini AJ; Martin DM; Turner CE
    Int J Psychiatry Med; 1990; 20(3):279-84. PubMed ID: 2265889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.
    Steiner M; Steinberg S; Stewart D; Carter D; Berger C; Reid R; Grover D; Streiner D
    N Engl J Med; 1995 Jun; 332(23):1529-34. PubMed ID: 7739706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine in the treatment of premenstrual dysphoria.
    Su TP; Schmidt PJ; Danaceau MA; Tobin MB; Rosenstein DL; Murphy DL; Rubinow DR
    Neuropsychopharmacology; 1997 May; 16(5):346-56. PubMed ID: 9109106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is 5HT1A receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study.
    Yatham LN
    Can J Psychiatry; 1993 Dec; 38(10):662-4. PubMed ID: 8313305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder.
    Girdler SS; Straneva PA; Light KC; Pedersen CA; Morrow AL
    Biol Psychiatry; 2001 May; 49(9):788-97. PubMed ID: 11331087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate variability in premenstrual dysphoric disorder.
    Landén M; Wennerblom B; Tygesen H; Modigh K; Sörvik K; Ysander C; Ekman A; Nissbrandt H; Olsson M; Eriksson E
    Psychoneuroendocrinology; 2004 Jul; 29(6):733-40. PubMed ID: 15110922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atenolol treatment of late luteal phase dysphoric disorder.
    Rausch JL; Janowsky DS; Golshan S; Kuhn K; Risch SC
    J Affect Disord; 1988; 15(2):141-7. PubMed ID: 2975684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin A levels in premenstrual syndrome.
    Chuong CJ; Dawson EB; Smith ER
    Fertil Steril; 1990 Oct; 54(4):643-7. PubMed ID: 2120085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased imidazoline and alpha 2 adrenergic binding in platelets of women with dysphoric premenstrual syndromes.
    Halbreich U; Piletz JE; Carson S; Halaris A; Rojansky N
    Biol Psychiatry; 1993 Nov; 34(10):676-86. PubMed ID: 7904832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.